Key indicators: single-crystal X-ray study; T = 273 K; mean (C-C) = 0.003 Å; R factor = 0.042; wR factor = 0.122; data-to-parameter ratio = 12.5.
Experimental
Crystal data Table 1 Hydrogen-bond geometry (Å , ) . ities such as antiviral, antibacterial, antifungal, antiulcer, and anti-inflammatory behavior (Jia et al., 2010) . Drugs containing imidazo[1,2-a]pyridines such as Alpidem, Zolpidem, Necopidem, Olprinone, Divalpon and Zolimidine are currently available on the market. In continuation of our work in this direction, we report here the crystal structure of the title compound, (I).
The title compound, C 16 H 13 N 3 O 4 , the imidazo[1,2-a]pyridine ring (N2/N3/C1-C7) and benzene ring (C11-C16) make a dihedral angles of 56.21 (2) °. π-π interactions are indicated by the short distance (Cg1···Cg2 distance of 3.787 (2) Å, symmetry code: x,1/2 -y,-1/2 + z) between the centroids of the pyridine ring (N2/C3-C7) (Cg1) and benzene ring C11-C16 (Cg2) ( Table 1 ). There are weaker C-H···O intermolecular interactions, which stabilize the structure (Table 1) .
To a 50-ml round-bottomed flask were added ethyl 4-bromobut-2-enoate (1.20 mmol), (1H-imidazol-2-yl)(4-nitrophenyl)methanone (1.00 mmol), potassium carbonate (0.283 g, 2.05 mmol) and dry DMF (10 ml). The mixture was stirred at rt for 3 h and then filtered. The filtrate was poured into water (100 ml) and extracted with CH 2 Cl 2 (three times per 30 ml). The combined extracts were washed with water, dried over anhydrous MgSO 4 and filtered, and the solvent was removed by rotary evaporation. The crude product were purified by column chromatography. Crystals of (I) suitable for X-ray diffraction was obtained by slow evaporation of a solution of the product in ethyl acetate at room temperature for 2 d.
Refinement
H atoms were positioned geometrically and refined using a riding model, with C-H = 0.93 or 0.97Å and with U iso (H) = 1.2U eq (C) and 1.5U eq (C) for methyl H atoms. 
